Platelet detection as a new liquid biopsy tool for human cancers

作者：Maoshan Chen, Lijia Hou, Lanyue Hu, Chengning Tan, Xiaojie Wang, Peipei Bao, Qian Ran, Li Chen, Zhongjun Li · 发表于：Frontiers in Oncology · 年份：2022 · DOI：10.3389/fonc.2022.983724 · 被引用次数：14 · 研究领域：Inflammatory Biomarkers in Disease Prognosis、Extracellular vesicles in disease、Platelet Disorders and Treatments

Cancer is still a leading cause of death worldwide and liquid biopsy is a powerful tool that can be applied to different stages of cancer screening and treatment. However, as the second most abundant cell type in the bloodstream, platelets are isolated through well-established and fast methods in clinic but their value as a BioSource of cancer biomarkers is relatively recent. Many studies demonstrated the bidirectional interaction between cancer cells and platelets. Platelets transfer various proteins (e.g., growth factors, cytokine, chemokines) and RNAs (e.g., mRNA, lncRNA, miRNA, circRNA) into the tumor cells and microenvironment, leading the stimulation of tumor growth and metastasis. In turn, the platelet clinical characteristics (e.g., count and volume) and contents (e.g., RNA and protein) are altered by the interactions with cancer cells and this enables the early cancer detection using these features of platelets. In addition, platelet-derived microparticles also demonstrate the prediction power of being cancer biomarkers. In this review, we focus on the clinical applications of platelet detection using the platelet count, mean platelet volume, platelet RNA and protein profiles for human cancers and discuss the gap in bringing these implementations into the clinic.